Skip to main content
. 2019 Aug 29;366:l4772. doi: 10.1136/bmj.l4772

Fig 3.

Fig 3

Subgroup analyses of association between use of SGLT2 inhibitors and use of DPP4 inhibitors and risk of major cardiovascular events and heart failure. SGLT2=sodium-glucose cotransporter 2; DDP4=dipeptidyl peptidase 4